Shanghai Henlius CEO Wants To Capitalize On First-Mover Status
Scott Liu Sets Out Ambitions That Go Beyond China
In an exclusive interview with Generics Bulletin, Dr. Scott Liu, co-founder, and CEO of Chinese biosimilars and biologics specialist Shanghai Henlius Biotech, has set out his vision for the firm’s future in China and around the globe.
You may also be interested in...
Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essexor biosimilar bevacizumab to treat ophthalmic diseases.
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.